AgomAb Therapeutics NV (AGMB) Stock Price & Analysis
AgomAb Therapeutics NV (AGMB) is trading at USD 5.74, down 3.04% today, as of November 18, 2026 at 20:52 UTC (US market open; quotes may be delayed), according to Nexqual market data.
AGMB last closed at USD 5.92; today's session has ranged USD 5.7–6.25 on volume of 97,063 shares. Market capitalization is $282.68M, with a 52-week range of USD 5.5–17.82 (NMS). Source: Nexqual, retrieved November 18, 2026 at 20:53 UTC.
What changed for AGMB since Aug 31, 2025
The built-in knowledge of several widely used AI models ends around Aug 31, 2025. Everything below is newer, dated and sourced (as of Nov 18, 2026).
- Analyst actions on AGMB in the last 120 days: 3 (0 upgrades or target raises, 0 downgrades or target cuts); most recent Piper Sandler, Aug 25, 2026.
Also available as compact Markdown for AI agents: nexqual.com/AGMB.md
Key facts (AGMB)
- Insider open-market purchases, last ~7 months: 7 Form 4 filings, $592K; 0 by opportunistic insiders, 0 by routine insiders.
- Analysts: Buy (mean 1.57 on a 1–5 scale) (7 analysts), mean target USD 37.67 (range 28–60).
- Total return with dividends: 1Y -60.8% vs S&P 500 +11.9%; 5Y -60.8% vs S&P 500 +66.7%.
- Dividend: AGMB paid no cash dividend in the last five years.
- Short interest: 2.26% of float (as of 2026-10-30), 6.1 days to cover.
Insider purchases (SEC Form 4, open-market, last ~7 months) (AGMB)
7 purchases, $592K. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-11-13 | Epstein David R | Director | 14,980 | $89K | 5.92 | Too little history (no open-market trades in 2023–2025) |
| 2026-11-05 | Epstein David R | Director | 15,000 | $104K | 6.9 | Too little history (no open-market trades in 2023–2025) |
| 2026-10-21 | Epstein David R | Director | 10,000 | $89K | 8.88 | Too little history (no open-market trades in 2023–2025) |
| 2026-10-08 | Epstein David R | Director | 5,000 | $45K | 8.9 | Too little history (no open-market trades in 2023–2025) |
| 2026-10-05…2026-10-06 | Epstein David R | Director | 10,000 | $86K | 8.63 | Too little history (no open-market trades in 2023–2025) |
| 2026-10-06 | Kemula Pierre Thadee Victor | Chief Financial Officer | 10,000 | $86K | 8.59 | Too little history (no open-market trades in 2023–2025) |
| 2026-10-05…2026-10-06 | Knotnerus Tim Jasper | Chief Executive Officer | 11,000 | $94K | 8.58 | Too little history (no open-market trades in 2023–2025) |
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (AGMB)
Consensus Buy (mean 1.57 on a 1–5 scale), 7 analysts; mean target USD 37.67 (low 28, high 60).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-25 | Piper Sandler | Initiated | Overweight | $60 |
| 2026-08-19 | Cantor Fitzgerald | Initiated | Overweight | |
| 2026-07-23 | B. Riley Securities | Initiated | Buy | $34 |
Total return (dividends reinvested) (AGMB)
| 1Y (from 2026-02-06) | 5Y (from 2026-02-02) | |
|---|---|---|
| Total return | -60.8% | -60.8% |
| S&P 500 (SPY) | +11.9% | +66.7% |
| Per year | — | — |
| Volatility (annualized) | 91.9% | 74.7% |
| Max drawdown | -67.8% (Jun 2026→Nov 2026) | -64.2% (Feb 2026→Nov 2026) |
Dividends (AGMB)
AGMB paid no cash dividend in the last five years.
Short interest (AGMB)
920,851 shares sold short, 2.26% of the float, as of Oct 30, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 30, 2026): 1,001,145 shares (-8.0%). Days to cover: 6.1 (short shares ÷ average daily volume).
AGMB recent SEC filings (last 120 days)
| Filed | Form | What it says |
|---|---|---|
| Nov 16, 2026 | Schedule 13G/A | Redmile Group, LLC, Jeremy C. Green: 3.5% of shares, passive 5%+ holder (amended) |
| Oct 13, 2026 | 6-K | Current report (foreign issuer) · period ended Oct 13, 2026 |
| Oct 1, 2026 | 6-K | Current report (foreign issuer) · period ended Oct 1, 2026 |
| Sep 14, 2026 | 6-K | Current report (foreign issuer) · period ended Sep 14, 2026 |
| Sep 11, 2026 | 6-K | Current report (foreign issuer) · period ended Sep 11, 2026 |
| Aug 10, 2026 | 6-K | Current report (foreign issuer) · period ended Aug 10, 2026 |
| Aug 6, 2026 | 6-K | Current report (foreign issuer) · period ended Aug 6, 2026 |
Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.
AGMB analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.36 | $-0.48 | +$0.12 | $0 | 3 |
| Next quarter (ends Dec 2026) | $-0.42 | $-0.54 | +$0.13 | $0 | 3 |
| Current fiscal year (ends Dec 2026) | $-1.81 | $-1.85 | +$0.05 | $0 | 6 |
| Next fiscal year (ends Dec 2027) | $-2.02 | $-2.08 | +$0.06 | $0 | 6 |
Key Statistics (as of November 18, 2026 at 20:53 UTC)
| Price | USD 5.74 |
|---|---|
| Change | ▼ 3.04% (down) |
| Previous Close | USD 5.92 |
| Open | USD 6 |
| Day Range | USD 5.7 – 6.25 |
| 52-Week Range | USD 5.5 – 17.82 |
| Volume | 97,063 shares |
| Market Cap | $282.68M |
| Exchange | NMS |
Technical Analysis (AGMB)
Nexqual's technical model rates AGMB "SELL" based on 2 bullish and 5 bearish signals across 129 daily candles, as of November 18, 2026 at 20:53 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 26.17 (oversold) |
| vs SMA50 | Below (USD 9.01) |
| MACD | -0.88 (negative) |
Analyst Ratings (AGMB)
Wall Street analysts rate AGMB "Buy" based on 7 analysts, with a mean price target of USD 37.67 (range USD 28–60), per Nexqual as of November 18, 2026 at 20:53 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 7 |
| Mean Target | USD 37.67 |
| High Target | USD 60 |
| Low Target | USD 28 |
| Buy / Hold / Sell | 7 / 0 / 0 |
Earnings (AGMB)
| EPS Estimate | USD -0.37 |
|---|---|
| Revenue Estimate | $0 |
Source: Nexqual, November 18, 2026 at 20:53 UTC.
Financials & Fundamentals (AGMB)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Debt / Equity | 0 |
| Current Ratio | 12.88 |
| Total Cash | $251.98M |
| Total Debt | $1.14M |
Source: Nexqual, November 18, 2026 at 20:53 UTC.
Financial Health Score (AGMB)
Nexqual rates AgomAb Therapeutics NV's overall financial health "Mixed" across five dimensions, as of November 18, 2026 at 20:53 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — EUR 252M cash vs EUR 1M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -EUR 57M (TTM) |
| Efficiency | Mixed — No data |
Ownership (AGMB)
| Insider Ownership | +10.27% |
|---|---|
| Institutional Ownership | +53.68% |
| Shares Outstanding | 49.25M |
| Float | 19.32M |
| Short % of Float | +2.26% |
Source: Nexqual, November 18, 2026 at 20:53 UTC.
Leadership (AGMB)
AgomAb Therapeutics NV is led by Tim Knotnerus MSc, CEO & Executive Director, per Nexqual as of November 18, 2026 at 20:53 UTC.
| CEO & Executive Director | Tim Knotnerus MSc |
|---|---|
| Chief Financial Officer | Pierre Kemula B.Sc. |
| Vice President of Investor Relations | Sofie Van Gijsel |
Major Backers & Investors (AGMB)
Notable institutional backers of AgomAb Therapeutics NV include Eqt Fund Management S.a R.l., Sanofi, Cormorant Asset Management, LP, according to Nexqual as of November 18, 2026 at 20:53 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Eqt Fund Management S.a R.l. | 10.44% |
| Sanofi | 5.65% |
| Cormorant Asset Management, LP | 5.01% |
| Pfizer Inc | 4.37% |
| TCG Crossover Management, LLC | 3.7% |
| Nantahala Capital Management, LLC | 3.55% |
| Redmile Group, LLC | 3.53% |
| Federated Hermes, Inc. | 3.28% |
Source: Nexqual, November 18, 2026 at 20:53 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| KOD | Kodiak Sciences Inc | USD 97.7 | ▲ 0.93% |
| BLTE | Belite Bio, Inc | USD 156.45 | ▼ 0.81% |
| ORKA | Oruka Therapeutics, Inc. | USD 95.68 | ▼ 0.67% |
| IBRX | ImmunityBio, Inc. | USD 6.71 | ▲ 7.11% |
| IMVT | Immunovant, Inc. | USD 33.24 | ▲ 0.09% |
| CGON | CG Oncology, Inc. | USD 79.85 | ▲ 1.15% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: November 18, 2026 at 20:53 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt